Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).

Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).

Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).

Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.

Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.

Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.

Abstract: A number of methods may be utilized to correct for the first drop dissimilarity in drop-on-demand inkjet devices. Various collection processes, mass calculations and timing manipulation may be utilized to correct the first drop dissimilarity problem.

Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).

Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.

Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.

Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.

Abstract: Therapeutic agent delivery systems, which include a thermally-sensitive copolymer and optionally a therapeutic agent, are disclosed. The copolymer is water soluble and biodegradable and, in accordance with exemplary embodiments, includes hydrophobic and hydrophilic portions. The systems may include supplemental compounds, such as polymeric nanoparticles, micelle compounds, or a combination thereof, to further provide sustained release of the therapeutic agent.

Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.

Abstract: Therapeutic agent delivery systems, which include a thermally-sensitive copolymer and optionally a therapeutic agent, are disclosed. The copolymer is water soluble and biodegradable and, in accordance with exemplary embodiments, includes hydrophobic and hydrophilic portions. The systems may include supplemental compounds, such as polymeric nanoparticles, micelle compounds, or a combination thereof, to further provide sustained release of the therapeutic agent.

Abstract: This invention is in the field of medicinal intervention. The present invention relates to a device constructed from metals, polymers or other materials that are amenable to precise surface modifications and coupling with erodible agents methods for its use, wherein (1) the erodible agents, which contain active ingredients (medications), provide for acute control of cellular proliferation and (2) a pattered surface having milli, micron, and/or nano-sized micro-patterning characteristics imparts anti-proliferative properties over the long-term.

Abstract: A method for improving the morphology of drops ejected from inkjet dispensers results in a more accurate and repeatable process. The method involves shifting the dwell time from one corresponding to the first harmonic of the dispenser to a higher harmonic, for example, the third harmonic.

Abstract: A method for determining either the mass of one or more drops dispensed from an inkjet dispensing device or the concentration of dissolved solutes form one or more drops of a liquid of interest dispensed from an inkjet dispensing device utilizes UV visible spectroscopy. The UV absorption spectra of the constituents of the solution may be compared to predetermined calibration curves to accurately determine mass and concentrations of a single drop.

Abstract: The establishment of a stable acoustic environment within the individual channels of an inkjet printing device functions to allow the inkjet printing device to precisely deposit the same amount of a particular substance at one or more locations on an object. This is particularly relevant when the inkjet printing device is operated in the on-demand mode of operation.

Abstract: A method for improving the morphology of drops ejected from inkjet dispensers results in a more accurate and repeatable process. The method involves shifting the dwell time from one corresponding to the first harmonic of the dispenser to a higher harmonic, for example, the third harmonic.

Abstract: A method for determining either the mass of one or more drops dispensed from an inkjet dispensing device or the concentration of dissolved solutes form one or more drops of a liquid of interest dispensed from an inkjet dispensing device utilizes UV visible spectroscopy. The UV absorption spectra o the constituents of the solution may be compared to predetermined calibration curves to accurately determine mass and concentrations of a single drop.